195 related articles for article (PubMed ID: 29567511)
21. HLA Class I Antigen Processing Machinery Defects in Cancer Cells-Frequency, Functional Significance, and Clinical Relevance with Special Emphasis on Their Role in T Cell-Based Immunotherapy of Malignant Disease.
Seliger B; Ferrone S
Methods Mol Biol; 2020; 2055():325-350. PubMed ID: 31502159
[TBL] [Abstract][Full Text] [Related]
22. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
23. MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer.
Kim YA; Lee HJ; Heo SH; Park HS; Park SY; Bang W; Song IH; Park IA; Gong G
Breast Cancer Res Treat; 2016 Apr; 156(3):597-606. PubMed ID: 27075916
[TBL] [Abstract][Full Text] [Related]
24. Role of altered expression of HLA class I molecules in cancer progression.
Aptsiauri N; Cabrera T; Mendez R; Garcia-Lora A; Ruiz-Cabello F; Garrido F
Adv Exp Med Biol; 2007; 601():123-31. PubMed ID: 17712999
[TBL] [Abstract][Full Text] [Related]
25. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.
Sundara YT; Kostine M; Cleven AH; Bovée JV; Schilham MW; Cleton-Jansen AM
Cancer Immunol Immunother; 2017 Jan; 66(1):119-128. PubMed ID: 27853827
[TBL] [Abstract][Full Text] [Related]
26. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
27. Involvement of HLA class I molecules in the immune escape of urologic tumors.
Carretero R; Gil-Julio H; Vázquez-Alonso F; Garrido F; Castiñeiras J; Cózar JM
Actas Urol Esp; 2014 Apr; 38(3):192-9. PubMed ID: 24315763
[TBL] [Abstract][Full Text] [Related]
28. Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies.
Seliger B
HLA; 2016 Nov; 88(5):213-220. PubMed ID: 27659281
[TBL] [Abstract][Full Text] [Related]
29. Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations.
Aptsiauri N; Carretero R; Garcia-Lora A; Real LM; Cabrera T; Garrido F
Cancer Immunol Immunother; 2008 Nov; 57(11):1727-33. PubMed ID: 18491093
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma.
Trieb K; Lechleitner T; Lang S; Windhager R; Kotz R; Dirnhofer S
Pathol Res Pract; 1998; 194(10):679-84. PubMed ID: 9820863
[TBL] [Abstract][Full Text] [Related]
31. Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial.
Zhang S; Kohli K; Black RG; Yao L; Spadinger SM; He Q; Pillarisetty VG; Cranmer LD; Van Tine BA; Yee C; Pierce RH; Riddell SR; Jones RL; Pollack SM
Cancer Immunol Res; 2019 Aug; 7(8):1237-1243. PubMed ID: 31171504
[TBL] [Abstract][Full Text] [Related]
32. Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype.
Garrido F; Romero I; Aptsiauri N; Garcia-Lora AM
Int J Cancer; 2016 Jan; 138(2):271-80. PubMed ID: 25471439
[TBL] [Abstract][Full Text] [Related]
33. Human leukocyte antigen-G (HLA-G) as a marker for diagnosis, prognosis and tumor immune escape in human malignancies.
Yie SM; Hu Z
Histol Histopathol; 2011 Mar; 26(3):409-20. PubMed ID: 21210353
[TBL] [Abstract][Full Text] [Related]
34. Cancer Immunology: Immune Escape of Tumors-Expression and Regulation of HLA Class I Molecules and Its Role in Immunotherapies.
Wang Y; Jasinski-Bergner S; Wickenhauser C; Seliger B
Adv Anat Pathol; 2023 May; 30(3):148-159. PubMed ID: 36517481
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.
Chung YR; Kim HJ; Jang MH; Park SY
Breast Cancer Res Treat; 2017 Feb; 161(3):409-420. PubMed ID: 27913931
[TBL] [Abstract][Full Text] [Related]
36. Genetic evolution of T-cell resistance in the course of melanoma progression.
Sucker A; Zhao F; Real B; Heeke C; Bielefeld N; Maβen S; Horn S; Moll I; Maltaner R; Horn PA; Schilling B; Sabbatino F; Lennerz V; Kloor M; Ferrone S; Schadendorf D; Falk CS; Griewank K; Paschen A
Clin Cancer Res; 2014 Dec; 20(24):6593-604. PubMed ID: 25294904
[TBL] [Abstract][Full Text] [Related]
37. HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2.
Kooi S; Zhang HZ; Patenia R; Edwards CL; Platsoucas CD; Freedman RS
Cell Immunol; 1996 Dec; 174(2):116-28. PubMed ID: 8954611
[TBL] [Abstract][Full Text] [Related]
38. HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy.
Anderson P; Aptsiauri N; Ruiz-Cabello F; Garrido F
Cell Mol Immunol; 2021 Mar; 18(3):556-565. PubMed ID: 33473191
[TBL] [Abstract][Full Text] [Related]
39. MHC heterogeneity and response of metastases to immunotherapy.
Algarra I; Garrido F; Garcia-Lora AM
Cancer Metastasis Rev; 2021 Jun; 40(2):501-517. PubMed ID: 33860434
[TBL] [Abstract][Full Text] [Related]
40. The Challenges of HLA Class I Loss in Cancer Immunotherapy: Facts and Hopes.
Aptsiauri N; Garrido F
Clin Cancer Res; 2022 Dec; 28(23):5021-5029. PubMed ID: 35861868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
